GI 254023X: Selective ADAM10 Metalloprotease Inhibitor for Precise Cell Signaling and Vascular Integrity Research

Executive Summary: GI 254023X is a potent, selective inhibitor of ADAM10 (IC₅₀ = 5.3 nM), with >100-fold selectivity over ADAM17, supporting precision studies in cell signaling and apoptosis (APExBIO). It blocks ADAM10-mediated cleavage of substrates like fractalkine, impacting pathways such as Notch1 and modulating cellular adhesion and survival. In vitro, GI 254023X induces apoptosis in Jurkat T-leukemia cells and preserves endothelial barrier function against Staphylococcus aureus α-hemolysin. In vivo, it enhances vascular integrity and survival in BALB/c mice under bacterial toxin challenge. The compound's solubility and storage profile enable flexible integration into research workflows (APExBIO).

Biological Rationale

ADAM10 (EC 3.4.24.81) is a type I transmembrane metalloprotease essential for regulated ectodomain shedding of various cell surface proteins. It processes substrates such as Notch1, fractalkine (CX3CL1), and VE-cadherin, influencing cell-cell adhesion, migration, and signaling in both physiological and disease contexts (Satir et al., 2020). Dysregulation of ADAM10 activity is implicated in oncogenesis, neurodegeneration, and vascular barrier disruption. Selective inhibition of ADAM10 allows researchers to dissect specific sheddase-mediated signaling events without the confounding effects associated with broader-spectrum metalloprotease inhibitors (See related article; this article provides updated quantitative evidence and workflow guidance beyond the mechanistic overview).

Mechanism of Action of GI 254023X

GI 254023X is a small molecule with chemical formula C₂₁H₃₃N₃O₄ and a molecular weight of 391.5. It acts as a competitive inhibitor of ADAM10 by binding to its catalytic domain, thereby blocking the proteolytic cleavage of ADAM10-specific substrates. The compound exhibits an IC₅₀ of 5.3 nM for ADAM10 and demonstrates >100-fold selectivity over ADAM17, minimizing off-target effects on related metalloproteases (APExBIO). Inhibition of ADAM10 by GI 254023X prevents the constitutive cleavage of fractalkine, modulates Notch1 signaling, and inhibits downstream effects such as proliferation and survival in leukemia cells.

Evidence & Benchmarks

• GI 254023X exhibits an IC₅₀ of 5.3 nM against human recombinant ADAM10 under standard assay conditions (37°C, pH 7.5 buffer) (APExBIO).
• Demonstrates >100-fold selectivity over ADAM17, minimizing off-target inhibition (APExBIO).
• Blocks ADAM10-mediated cleavage of fractalkine (CX3CL1) and Notch1 in cellular assays (APExBIO).
• Induces apoptosis and inhibits proliferation in Jurkat T-lymphoblastic leukemia cells by modulating Notch1 and MCL-1 expression (see detailed apoptosis workflow; this dossier provides specific solubility and storage parameters).
• Prevents VE-cadherin cleavage and protects HPAEC monolayers from Staphylococcus aureus α-hemolysin-induced barrier disruption at 1–10 μM concentrations (APExBIO).
• In vivo, GI 254023X (200 mg/kg/day, i.p., 3 days) in BALB/c mice enhances vascular integrity and prolongs survival after lethal toxin challenge (APExBIO).
• Soluble at ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol, enabling high-concentration stock solutions for flexible dosing (APExBIO).

Applications, Limits & Misconceptions

GI 254023X is used in the following research areas:

• Dissection of ADAM10-dependent sheddase activity in cell signaling models (prior review details signaling applications; this article provides quantitative benchmarks and workflow parameters).
• Apoptosis induction and proliferation inhibition in acute T-lymphoblastic leukemia models.
• Protection of endothelial barrier integrity in response to bacterial toxins.
• Modulation of Notch1 signaling in developmental and oncogenic pathways.

Common Pitfalls or Misconceptions

• GI 254023X is not suitable for in vivo studies requiring oral administration due to poor water solubility; use intraperitoneal injection for animal models.
• It does not inhibit γ-secretase or BACE1; its effects are limited to ADAM10-dependent pathways (Satir et al., 2020).
• Long-term storage of GI 254023X solutions in DMSO at room temperature leads to compound degradation; store at -20°C and prepare fresh solutions as needed.
• Not intended for therapeutic or diagnostic use in humans; for research use only (RUO).
• Off-target effects may occur at concentrations above 10 μM; always titrate for minimal effective dose.

Workflow Integration & Parameters

GI 254023X is supplied as a white solid by APExBIO. For in vitro use, stock solutions can be prepared at concentrations >10 mM in DMSO (≥42.6 mg/mL) and ethanol (≥46.1 mg/mL); the compound is insoluble in water. For optimal solubility, gentle warming (37°C) and brief sonication are recommended. For cell culture assays, final DMSO concentrations should not exceed 0.1–0.2% to avoid solvent cytotoxicity. For animal studies, GI 254023X is administered intraperitoneally at 200 mg/kg/day for 3 days in BALB/c mouse models (APExBIO). Storage at -20°C is mandatory, with avoidance of repeated freeze-thaw cycles. The A4436 kit supports integration into established sheddase-dependent signaling, apoptosis, and vascular integrity protocols. For advanced guidance on model selection and experimental design, see this article, which focuses on disease model boundaries not covered in this dossier.

Conclusion & Outlook

GI 254023X (A4436) is a benchmark ADAM10 inhibitor for selective, high-fidelity interrogation of sheddase-mediated processes in translational research, with robust evidence supporting its use in oncology and vascular biology. Its nanomolar potency and high selectivity enable dissection of ADAM10-dependent pathways with minimal off-target effects. APExBIO provides this compound for research use only, with detailed storage and workflow guidelines to maximize reproducibility. As preclinical applications expand, GI 254023X will remain a preferred tool for mechanistic studies in cell signaling, apoptosis, and endothelial barrier research (APExBIO).